Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

A. Brisuda, JCS. Ho, PS. Kandiyal, JT. Ng, I. Ambite, DSC. Butler, J. Háček, MLY. Wan, TH. Tran, A. Nadeem, TH. Tran, A. Hastings, P. Storm, DL. Fortunati, P. Esmaeili, H. Novotna, J. Horňák, YG. Mu, KH. Mok, M. Babjuk, C. Svanborg

. 2021 ; 12 (1) : 3427. [pub] 20210608

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze I, klinické zkoušky, fáze II, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018462

Partially unfolded alpha-lactalbumin forms the oleic acid complex HAMLET, with potent tumoricidal activity. Here we define a peptide-based molecular approach for targeting and killing tumor cells, and evidence of its clinical potential (ClinicalTrials.gov NCT03560479). A 39-residue alpha-helical peptide from alpha-lactalbumin is shown to gain lethality for tumor cells by forming oleic acid complexes (alpha1-oleate). Nuclear magnetic resonance measurements and computational simulations reveal a lipid core surrounded by conformationally fluid, alpha-helical peptide motifs. In a single center, placebo controlled, double blinded Phase I/II interventional clinical trial of non-muscle invasive bladder cancer, all primary end points of safety and efficacy of alpha1-oleate treatment are reached, as evaluated in an interim analysis. Intra-vesical instillations of alpha1-oleate triggers massive shedding of tumor cells and the tumor size is reduced but no drug-related side effects are detected (primary endpoints). Shed cells contain alpha1-oleate, treated tumors show evidence of apoptosis and the expression of cancer-related genes is inhibited (secondary endpoints). The results are especially encouraging for bladder cancer, where therapeutic failures and high recurrence rates create a great, unmet medical need.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018462
003      
CZ-PrNML
005      
20210830100039.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-021-23748-y $2 doi
035    __
$a (PubMed)34103518
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Brisuda, Antonín $u Department of Urology, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
245    10
$a Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex / $c A. Brisuda, JCS. Ho, PS. Kandiyal, JT. Ng, I. Ambite, DSC. Butler, J. Háček, MLY. Wan, TH. Tran, A. Nadeem, TH. Tran, A. Hastings, P. Storm, DL. Fortunati, P. Esmaeili, H. Novotna, J. Horňák, YG. Mu, KH. Mok, M. Babjuk, C. Svanborg
520    9_
$a Partially unfolded alpha-lactalbumin forms the oleic acid complex HAMLET, with potent tumoricidal activity. Here we define a peptide-based molecular approach for targeting and killing tumor cells, and evidence of its clinical potential (ClinicalTrials.gov NCT03560479). A 39-residue alpha-helical peptide from alpha-lactalbumin is shown to gain lethality for tumor cells by forming oleic acid complexes (alpha1-oleate). Nuclear magnetic resonance measurements and computational simulations reveal a lipid core surrounded by conformationally fluid, alpha-helical peptide motifs. In a single center, placebo controlled, double blinded Phase I/II interventional clinical trial of non-muscle invasive bladder cancer, all primary end points of safety and efficacy of alpha1-oleate treatment are reached, as evaluated in an interim analysis. Intra-vesical instillations of alpha1-oleate triggers massive shedding of tumor cells and the tumor size is reduced but no drug-related side effects are detected (primary endpoints). Shed cells contain alpha1-oleate, treated tumors show evidence of apoptosis and the expression of cancer-related genes is inhibited (secondary endpoints). The results are especially encouraging for bladder cancer, where therapeutic failures and high recurrence rates create a great, unmet medical need.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a endocytóza $x účinky léků $7 D004705
650    _2
$a stanovení cílového parametru $7 D023381
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny olejové $x chemie $7 D009829
650    _2
$a peptidy $x chemie $x farmakologie $x terapeutické užití $7 D010455
650    _2
$a placebo $7 D010919
650    _2
$a konformace proteinů $7 D011487
650    _2
$a protonová magnetická rezonanční spektroskopie $7 D066244
650    _2
$a termodynamika $7 D013816
650    _2
$a nádory močového měchýře $x farmakoterapie $x genetika $x patologie $7 D001749
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ho, James C S $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden $u Centre for Biomimetic Sensor Science, Nanyang Technological University, Singapore, Singapore
700    1_
$a Kandiyal, Pancham S $u Trinity Biomedical Sciences Institute (TBSI), School of Biochemistry & Immunology, Trinity College Dublin, The University of Dublin, Dublin, Ireland
700    1_
$a Ng, Justin T-Y $u School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
700    1_
$a Ambite, Ines $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Butler, Daniel S C $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Háček, Jaromir $u Department of Pathology and Molecular Medicine, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
700    1_
$a Wan, Murphy Lam Yim $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Tran, Thi Hien $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Nadeem, Aftab $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Tran, Tuan Hiep $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Hastings, Anna $u Trinity Biomedical Sciences Institute (TBSI), School of Biochemistry & Immunology, Trinity College Dublin, The University of Dublin, Dublin, Ireland
700    1_
$a Storm, Petter $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Fortunati, Daniel L $u Trinity Biomedical Sciences Institute (TBSI), School of Biochemistry & Immunology, Trinity College Dublin, The University of Dublin, Dublin, Ireland
700    1_
$a Esmaeili, Parisa $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden
700    1_
$a Novotna, Hana $u Department of Urology, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
700    1_
$a Horňák, Jakub $u Department of Urology, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
700    1_
$a Mu, Y G $u School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
700    1_
$a Mok, K H $u Trinity Biomedical Sciences Institute (TBSI), School of Biochemistry & Immunology, Trinity College Dublin, The University of Dublin, Dublin, Ireland
700    1_
$a Babjuk, Marek $u Department of Urology, Motol University Hospital, 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
700    1_
$a Svanborg, Catharina $u Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden. catharina.svanborg@med.lu.se
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 12, č. 1 (2021), s. 3427
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34103518 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100039 $b ABA008
999    __
$a ok $b bmc $g 1689535 $s 1138906
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c 1 $d 3427 $e 20210608 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace